<unk>  appears in greater than 6% of children whose mothers took<unk>  during pregnancy.<unk>  has a low molecular weight so can pass from the maternal to<unk>  bloodstream through the tight filter-like junctions of the placental barrier. As the teratogenic effects of<unk>  are well known, the medication is rarely prescribed to pregnant women. However, for some patients, the risks associated with discontinuing<unk>  use may outweigh the risk of embryopathy. Patients with prosthetic heart valves carry a particularly high risk of thrombus formation due to the inorganic surface and turbulent blood flow generated by a mechanical prosthesis. The risk of blood clotting is further increased by generalized hypercoagulability as concentrations of clotting factors rise during pregnancy. This increased chance of blood clots leads to an increased risk of potentially<unk>  pulmonary or systemic emboli cutting off blood flow and oxygen to critical organs. Thus, some patients may continue taking<unk>  throughout the pregnancy despite the risks to the developing child.
Fetal warfarin syndrome
Neonatal sepsis
Fetal hydantoin syndrome
Shaken baby syndrome
Neonatal stroke
Fetal trimethadione syndrome
Neonatal meningitis
Uremic fetor